The EACH/PIC Coalition submitted written testimony to the House Committee on Government Operations and the Senate Committee on Finance ahead of consideration of H.B. 424/S.B. 357. The letter urged both […]
The EACH Coalition submitted letters to the Maryland PDAB ahead of expected cost reviews of the two drugs Jardiance and Farxiga. Prior to the meeting, the board revised its agenda
The EACH/PIC Coalition submitted a comment letter to the Labor and Commerce Committee in the Virginia House of Delegates. The letter opposed HB1724 which would establish a Prescription Drug Affordability
As the Washington PDAB finalizes policies for its drug review process, the EACH Coalition submitted comments to the board emphasizing the importance of keeping patient perspective and impact centered throughout
The EACH Coalition submitted comments to the Oregon board on the board’s annual policies. The letter included comments on posting deadlines, comment periods, and conflict of interest policies.
The EACH Coalition submitted comments to the Oregon board on the proposed policy recommendations and draft annual PDAB report. The letter applauded board recommendations that would require more transparency around
The EACH Coalition submitted comments to the Colorado board on the updated redline versions of the affordability rule and policy and procedures prior to deliberations on both during the December
The EACH Coalition submitted comments to the board providing input for their planned report to the Oregon legislature on a plan to implement UPL policies in the state. The letter
The EACH Coalition submitted letters to the MD PDAB in response to a request for input on the first 4 drugs selected for cost reviews by the board. The letters
The EACH Coalition submitted comments to the MD PDAB in response to requested input on COMAR 14.01.05 (Policy Review, Final Action, Upper Payment Limits). The letter urged the board to
